Form 4: Edgewise Therapeutics Executive Exercises Options and Sells Shares
SEC Form 4 Filing
Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, exercised stock options and sold shares on September 20, 2024.
Summary
- On September 20, 2024, Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics, exercised stock options to acquire 42,068 shares of common stock at a price of $1.93 per share.
- Simultaneously, Derakhshan sold 42,068 shares of common stock at an average price of $29.0276 per share, with prices ranging from $29.00 to $29.28.
- Following these transactions, Derakhshan beneficially owns 15,121 shares of common stock directly and holds options for 102,949 shares.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative implications for the company's overall prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It's common for executives to exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| January 3, 2021 | Start date for monthly vesting of stock options. |
| May 15, 2024 | Purchase of 1,699 shares through the Employee Stock Purchase Plan. |
| September 20, 2024 | Date of stock option exercise and share sale. |
| September 24, 2024 | Date of Form 4 filing. |
| December 15, 2030 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.